Erisa Sabakaki Mwaka1,2, Ian Guyton Munabi1, Barbara Castelnuovo2, Arvind Kaimal2, William Kasozi2, Andrew Kambugu1, Philippa Musoke3, Elly Katabira4. 1. School of Biomedical Sciences, College of Health Sciences, Makerere University, Kampala, Uganda. 2. Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. 3. Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda. 4. Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
Abstract
BACKGROUND: This study set out to determine the prevalence of low bone mass following long-term exposure to antiretroviral therapy in Ugandan people living with HIV. METHODS: A cross-sectional study was conducted among 199 people living with HIV that had been on anti-retroviral therapy for at least 10 years. All participants had dual X-ray absorptiometry to determine their bone mineral density. The data collected included antiretroviral drug history and behavioral risk data Descriptive statistics were used to summarize the data. Inferential statistics were analyzed using multilevel binomial longitudinal Markov chain Monte Carlo mixed multivariate regression modelling using the rstanarm package. RESULTS: One hundred ninety nine adults were enrolled with equal representation of males and females. The mean age was 39.5 (SD 8.5) years. Mean durations on anti-retroviral treatment was 12.1 (SD 1.44) years, CD4 cell count was 563.9 cells/mm3. 178 (89.5%) had viral suppression with <50 viral copies/ml. There were 4 (2.0%) and 36 (18%) participants with low bone mass of the hip and lumbar spine respectively. Each unit increase in body mass index was associated with a significant reduction in the odds for low bone mineral density of the hip and lumbar spine. The duration on and exposure to the various antiretroviral medications had no significant effect on the participant's odds for developing low bone mass. All the coefficients of the variables in a multivariable model for either hip or lumbar spine bone mass were not significant. CONCLUSION: These results provide additional evidence that patients on long term ART achieve bone mass stabilization. Maintaining adequate body weight is important in maintaining good bone health in people on antiretroviral therapy.
BACKGROUND: This study set out to determine the prevalence of low bone mass following long-term exposure to antiretroviral therapy in Ugandan people living with HIV. METHODS: A cross-sectional study was conducted among 199 people living with HIV that had been on anti-retroviral therapy for at least 10 years. All participants had dual X-ray absorptiometry to determine their bone mineral density. The data collected included antiretroviral drug history and behavioral risk data Descriptive statistics were used to summarize the data. Inferential statistics were analyzed using multilevel binomial longitudinal Markov chain Monte Carlo mixed multivariate regression modelling using the rstanarm package. RESULTS: One hundred ninety nine adults were enrolled with equal representation of males and females. The mean age was 39.5 (SD 8.5) years. Mean durations on anti-retroviral treatment was 12.1 (SD 1.44) years, CD4 cell count was 563.9 cells/mm3. 178 (89.5%) had viral suppression with <50 viral copies/ml. There were 4 (2.0%) and 36 (18%) participants with low bone mass of the hip and lumbar spine respectively. Each unit increase in body mass index was associated with a significant reduction in the odds for low bone mineral density of the hip and lumbar spine. The duration on and exposure to the various antiretroviral medications had no significant effect on the participant's odds for developing low bone mass. All the coefficients of the variables in a multivariable model for either hip or lumbar spine bone mass were not significant. CONCLUSION: These results provide additional evidence that patients on long term ART achieve bone mass stabilization. Maintaining adequate body weight is important in maintaining good bone health in people on antiretroviral therapy.
Authors: Lauro F S Pinto Neto; Sergio Ragi-Eis; Nilo F R Vieira; Moacir Soprani; Mariza B Neves; Rodrigo Ribeiro-Rodrigues; Angelica E Miranda Journal: J Clin Densitom Date: 2011 Oct-Dec Impact factor: 2.617
Authors: Grace A McComsey; Douglas Kitch; Eric S Daar; Camlin Tierney; Nasreen C Jahed; Pablo Tebas; Laurie Myers; Kathleen Melbourne; Belinda Ha; Paul E Sax Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: G Madeddu; A Spanu; P Solinas; S Babudieri; G M Calia; C Lovigu; M Mannazzu; S Nuvoli; B Piras; P Bagella; M S Mura; G Madeddu Journal: Eur Rev Med Pharmacol Sci Date: 2015-12 Impact factor: 3.507
Authors: Hans-Jürgen Stellbrink; Chloe Orkin; Jose Ramon Arribas; Juliet Compston; Jan Gerstoft; Eric Van Wijngaerden; Adriano Lazzarin; Giuliano Rizzardini; Herman G Sprenger; John Lambert; Gunta Sture; David Leather; Sara Hughes; Patrizia Zucchi; Helen Pearce Journal: Clin Infect Dis Date: 2010-10-15 Impact factor: 9.079
Authors: Barbara Castelnuovo; Agnes Kiragga; Victor Afayo; Malisa Ncube; Richard Orama; Stephen Magero; Peter Okwi; Yukari C Manabe; Andrew Kambugu Journal: PLoS One Date: 2012-12-17 Impact factor: 3.240